Final Decision: HOLD

Reason: While there are positive sentiments from analysts at Motilal Oswal and HSBC, citing upside potential, the regulatory challenges faced by Sun Pharma's Dadra plant, including the FDA's OAI status, pose a short-term uncertainty, offsetting the positives.